Fidelity Investments
ACRS icon

Fidelity Investments’s Aclaris Therapeutics ACRS Stock Holding History

Fidelity Investments’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$661K Buy
176,353
+130,546
+285% +$440K ﹤0.01% 3013
2025
Q4 		$138K Buy
45,807
+5,457
+14% +$13.8K ﹤0.01% 3597
2025
Q3 		$76.7K Sell
40,350
-401,897
-91% -$701K ﹤0.01% 3777
2025
Q2 		$628K Sell
442,247
-15,937
-3% -$21.6K ﹤0.01% 2886
2025
Q1 		$701K Sell
458,184
-865
-0.2% -$1.84K ﹤0.01% 2799
2024
Q4 		$1.14M Sell
459,049
-86,923
-16% -$216K ﹤0.01% 2626
2024
Q3 		$628K Sell
545,972
-143,381
-21% -$176K ﹤0.01% 2764
2024
Q2 		$758K Buy
689,353
+17,525
+3% +$20.6K ﹤0.01% 2603
2024
Q1 		$833K Buy
671,828
+1,114
+0.2% +$1.33K ﹤0.01% 2563
2023
Q4 		$704K Buy
670,714
+9,414
+1% +$28.7K ﹤0.01% 2576
2023
Q3 		$4.53M Sell
661,300
-86,765
-12% -$741K ﹤0.01% 2075
2023
Q2 		$7.76M Sell
748,065
-4,976
-0.7% -$45K ﹤0.01% 1940
2023
Q1 		$6.09M Sell
753,041
-19,435
-3% -$247K ﹤0.01% 2030
2022
Q4 		$12.2M Sell
772,476
-372,863
-33% -$6M ﹤0.01% 1816
2022
Q3 		$18M Sell
1,145,339
-96,969
-8% -$1.53M ﹤0.01% 1646
2022
Q2 		$17.3M Buy
1,242,308
+28,958
+2% +$406K ﹤0.01% 1704
2022
Q1 		$20.9M Sell
1,213,350
-266,639
-18% -$3.64M ﹤0.01% 1765
2021
Q4 		$21.5M Sell
1,479,989
-103,100
-7% -$1.56M ﹤0.01% 1790
2021
Q3 		$28.5M Sell
1,583,089
-108,885
-6% -$1.75M ﹤0.01% 1670
2021
Q2 		$29.7M Buy
1,691,974
+191,000
+13% +$4.34M ﹤0.01% 1674
2021
Q1 		$37.8M Buy
1,500,974
+1,294,990
+629% +$25.3M ﹤0.01% 1516
2020
Q4 		$1.33M Hold
205,984
– – ﹤0.01% 2478
2020
Q3 		$529K Hold
205,984
– – ﹤0.01% 2528
2020
Q2 		$334K Sell
205,984
-800
-0.4% -$1.07K ﹤0.01% 2548
2020
Q1 		$215K Buy
206,784
+800
+0.4% +$1.09K ﹤0.01% 2566
2019
Q4 		$389K Sell
205,984
-870
-0.4% -$1.44K ﹤0.01% 2528
2019
Q3 		$223K Sell
206,854
-1,165,056
-85% -$1.65M ﹤0.01% 2622
2019
Q2 		$3M Buy
1,371,910
+302,268
+28% +$1.65M ﹤0.01% 2238
2019
Q1 		$6.41M Sell
1,069,642
-994,967
-48% -$6.6M ﹤0.01% 2001
2018
Q4 		$15.3M Sell
2,064,609
-831,308
-29% -$8.57M ﹤0.01% 1656
2018
Q3 		$42M Sell
2,895,917
-459,868
-14% -$7.88M ﹤0.01% 1354
2018
Q2 		$67M Buy
3,355,785
+796,805
+31% +$14.7M 0.01% 1142
2018
Q1 		$44.8M Sell
2,558,980
-110,679
-4% -$2.35M 0.01% 1346
2017
Q4 		$65.8M Buy
2,669,659
+514,639
+24% +$12.5M 0.01% 1172
2017
Q3 		$55.6M Buy
2,155,020
+258,814
+14% +$6.94M 0.01% 1256
2017
Q2 		$51.4M Buy
1,896,206
+242,269
+15% +$6.59M 0.01% 1281
2017
Q1 		$49.3M Buy
1,653,937
+1,185,598
+253% +$34.2M 0.01% 1307
2016
Q4 		$12.7M Sell
468,339
-2,190,988
-82% -$55.9M ﹤0.01% 1879
2016
Q3 		$68.1M Sell
2,659,327
-130,571
-5% -$2.77M 0.01% 1165
2016
Q2 		$51.5M Sell
2,789,898
-1,014,381
-27% -$20.1M 0.01% 1261
2016
Q1 		$72.1M Hold
3,804,279
– – 0.01% 1110
2015
Q4 		$102M Buy
+3,804,279
New +$74.1M 0.01% 959

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fidelity Investments's ACRS Position: Q1 2026 in Review

Fidelity Investments increased its Aclaris Therapeutics (ACRS) stake by 285% in Q1 2026, buying an estimated $440K and bringing the position to 176,353 shares worth $661K. The position accounts for ﹤0.01% of the portfolio, ranked #3013.

Fidelity Investments first reported a position in ACRS in Q4 2015 and has held it in 42 quarters since. The position peaked at $102M in Q4 2015. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Fidelity Investments held 176,353 shares of Aclaris Therapeutics worth $661K as of Q1 2026.
  • Fidelity Investments bought 130,546 Aclaris Therapeutics shares in Q1 2026, an estimated $440K.
  • Aclaris Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q1 2026, its #3013 holding.
  • Fidelity Investments first reported a position in Aclaris Therapeutics in Q4 2015 and has held it in 42 quarters since.
  • Fidelity Investments's Aclaris Therapeutics position peaked at $102M in Q4 2015.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Fidelity Investments's 13F filing for Q1 2026, filed 15 May 2026.